Benefits
Traditional liver-channel use, with an important safety caution
This use comes from traditional Chinese medicine and from animal experiments, not from human trials. No controlled study has shown that bupleurum improves liver function in people. Bupleurum-containing formulas have themselves been linked to cases of liver injury, so this should not be read as a liver benefit.
Immune effects seen only in laboratory studies
Bupleurum polysaccharides and saikosaponins change immune-cell signaling in cell and animal experiments. Nothing about immune function has been measured in people taking bupleurum, so no immune benefit can be claimed.
Traditional use during periods of stress and tension
Bupleurum appears in classical multi-herb formulas given during periods of stress and irritability. This is traditional use only. No human trial has tested bupleurum for mood, stress, or anxiety.
Traditional use for stress-related digestive complaints
Classical formulas containing bupleurum were used for bloating and discomfort linked to stress. No human trial has tested bupleurum for digestive symptoms, and the gut-brain-liver mechanism language is theory rather than a measured effect.
Antioxidant activity seen in the laboratory only
Saikosaponins show antioxidant and anti-inflammatory activity in test-tube and animal models. These effects have not been demonstrated in people taking bupleurum.
Mechanism of action
Saikosaponin hepatoprotection
Saikosaponin A and D help protect hepatocytes from chemical injury in animal models by supporting glutathione status, modulating Kupffer-cell activation, and reducing lipid peroxidation.
Immunomodulation via polysaccharides
In cell and animal studies, bupleurum polysaccharides engage pattern-recognition receptors and change macrophage activity. Whether any of this happens in people taking bupleurum has not been tested.
HPA-axis modulation
Preclinical studies suggest saikosaponins modulate HPA-axis signaling and corticosterone responses, contributing to traditional stress-related uses.
Anti-inflammatory NF-κB inhibition
Saikosaponins inhibit NF-κB activation and downstream production of pro-inflammatory cytokines such as TNF-α and IL-6 in laboratory models.
Clinical trials
Single-arm phase II study with no control group, testing sho-sai-ko-to, a compound of seven botanical extracts of which bupleurum is only one
n=24 adults with chronic hepatitis C ineligible for interferon
AST improved in 16 of the 24 participants (67%) and ALT in 18 of 24 (75%). Everyone received the formula and there was no placebo or control group, so these numbers do not show an effect: liver enzymes rise and fall on their own in chronic hepatitis C. The product also contained seven herbs, so nothing here can be credited to bupleurum. This was a study in people already diagnosed with a liver disease, not a test of what bupleurum does for a healthy person.
Comprehensive pharmacology review of approximately 50 Bupleurum species and ~250 isolated compounds
Mixed in vitro, animal, and limited human evidence
This is a review article, not a study in people. It summarizes mostly test-tube and animal findings on saikosaponins, notes that extracts are poorly standardized, and points out that what little human evidence exists comes from multi-herb formulas rather than bupleurum on its own.